Literature DB >> 29306497

Short- and long-term risks of cardiovascular disease following radiotherapy in rectal cancer in four randomized controlled trials and a population-based register.

Lingjing Chen1, Sandra Eloranta2, Anna Martling3, Ingrid Glimelius4, Martin Neovius2, Bengt Glimelius5, Karin E Smedby2.   

Abstract

AIM: A population-based cohort and four randomized trials enriched with long-term register data were used to clarify if radiotherapy in combination with rectal cancer surgery is associated with increased risks of cardiovascular disease (CVD).
METHODS: We identified 14,901 rectal cancer patients diagnosed 1995-2009 in Swedish nationwide registers, of whom 9227 were treated with preoperative radiotherapy. Also, we investigated 2675 patients with rectal cancer previously randomized to preoperative radiotherapy or not followed by surgery in trials conducted 1980-1999. Risks of CVD overall and subtypes were estimated based on prospectively recorded hospital visits during relapse-free follow-up using multivariable Cox regression. Maximum follow-up was 18 and 33 years in the register and trials, respectively.
RESULTS: We found no association between preoperative radiotherapy and overall CVD risk in the register (Incidence Rate Ratio, IRR = 0.99, 95% confidence interval (CI) 0.92-1.06) or in the pooled trials (IRR = 1.07, 95% CI 0.93-1.24). We noted an increased risk of venous thromboembolism among irradiated patients in both cohorts (IRRregister = 1.41, 95% CI 1.15-2.72; IRRtrials = 1.41, 95% CI 0.97-2.04), that remained during the first 6 months following surgery among patients treated 2006-2009, after the introduction of antithrombotic treatment (IRR6 months = 2.30, 95% CI 1.01-5.21). However, the absolute rate difference of venous thromboembolism attributed to RT was low (10 cases per 1000 patients and year). DISCUSSION: Preoperative radiotherapy did not affect rectal cancer patients' risk of CVD overall. Although an excess risk of short-term venous thromboembolism was noted, the small increase in absolute numbers does not call for general changes in routine prophylactic treatment, but might do so for patients already at high risk of venous thromboembolism.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Long-term cardiovascular disease; Population-based cohorts; Radiotherapy; Randomized controlled trials; Rectal cancer; Venous thromboembolism

Mesh:

Year:  2018        PMID: 29306497     DOI: 10.1016/j.radonc.2017.12.008

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  4 in total

1.  Risk of heart failure among colon and rectal cancer survivors: a population-based case-control study.

Authors:  Josephina G Kuiper; Myrthe P P van Herk-Sukel; Valery E P P Lemmens; Mathijs J Kuiper; Ernst J Kuipers; Ron M C Herings
Journal:  ESC Heart Fail       Date:  2022-04-22

2.  Could Stoma Be Avoided after Laparoscopic Low Anterior Resection for Rectal Cancer? Experience with Transanal Tube in 195 Cases.

Authors:  Antonio Sciuto; Roberto Peltrini; Federica Andreoli; Andrea Gianmario Di Santo Albini; Maria Michela Di Nuzzo; Nello Pirozzi; Marcello Filotico; Federica Lauria; Giuseppe Boccia; Michele D'Ambra; Ruggero Lionetti; Carlo De Werra; Felice Pirozzi; Francesco Corcione
Journal:  J Clin Med       Date:  2022-05-07       Impact factor: 4.964

3.  Venous thromboembolism and radiation therapy: The final radiation-induced thrombosis study analysis.

Authors:  Elisabeth Daguenet; Mathilde Maison; Fabien Tinquaut; Eric-Alban Giroux; Laurent Bertoletti; Jean-Philippe Suchaud; Chloé Rancoule; Jean-Baptiste Guy; Nicolas Magné
Journal:  Cancer Med       Date:  2022-02-24       Impact factor: 4.711

4.  Association between Radiotherapy and Risk of Cancer Associated Venous Thromboembolism: A Sub-Analysis of the COMPASS-CAT Study.

Authors:  Sally Temraz; Nour Moukalled; Grigorios T Gerotziafas; Ismail Elalamy; Luis Jara-Palomares; Maya Charafeddine; Ali Taher
Journal:  Cancers (Basel)       Date:  2021-03-02       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.